John Marshall Bank Announces Expanded Support for Small Businesses through SBA Express Loan Program
John Marshall Bank has added the SBA Express product suite to further support small businesses throughout the DC Metro area which gives small businesses greater access to funding to help facilitate their growth and fulfill their goals.
Share
SBA Express loans and lines of credit have a maximum loan amount of $500,000 and provide the Bank with the authority to make loan decisions, including processing, closing, servicing, and more. This lower threshold and expedited process appeals to a broad audience of small business owners looking for the advantages of SBA financing. In tandem with the Bank's Preferred Lender Status, the Bank has proven capability of providing smart and effective financing options to small businesses.
'SBA Express gives small businesses greater access to funding to help facilitate their growth and fulfill their goals,' stated Jason McDonough, EVP, Chief Lending Officer. 'Along with benefitting from the expedited timeframe that SBA Express allows, our small business clients will receive the Bank's full suite of business banking services, financial products, and the partnership of our dedicated and responsive small business banking team.'
Along with SBA Express, the Bank offers standard SBA 7(a) loans, SBA 7(a) Small loans, SBA 504 loans, all of which are enhanced with the Bank's Preferred Lender Status, and other unique financing solutions for its small business clients. Beyond lending, the Bank has access to additional resources, educational materials, and workshops, provided by the SBA to further assist small business owners in utilizing their SBA loans. The Bank remains dedicated to the growth of its small business clients well past their loan closings extending through an ongoing partnership. For small businesses banking with John Marshall Bank, an SBA loan is just the beginning of a long-term financial relationship rooted in safety and soundness and dedicated to helping businesses move forward.
To apply for an SBA express loan, standard 7(a) loan, or any other type of SBA loan through John Marshall Bank, reach out to businessbanking@johnmarshallbank.com.
About John Marshall Bancorp, Inc.:
John Marshall Bancorp, Inc. is the bank holding company for John Marshall Bank. The Bank is headquartered in Reston, Virginia with eight full-service branches located in Alexandria, Arlington, Loudoun, Prince William, Reston, and Tysons, Virginia, as well as Rockville, Maryland, and Washington, D.C. The Bank is dedicated to providing exceptional value, personalized service and convenience to local businesses and professionals in the Washington D.C. Metro area. The Bank offers a comprehensive line of sophisticated banking products and services that rival those of the largest banks along with experienced staff to help achieve customers' financial goals. Dedicated Relationship Managers serve as direct points-of-contact, providing subject matter expertise in a variety of niche industries including Charter and Private Schools, Government Contractors, Health Services, Nonprofits and Associations, Professional Services, Property Management Companies and Title Companies. Learn more at www.johnmarshallbank.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Stock market today: Nasdaq pops, leading Dow and S&P 500 higher amid Vietnam trade deal, weak jobs data
US stocks moved higher on Wednesday as optimism over US trade deals rose at the same time that more signs of an intensifying labor market slowdown bolstered the case for the Federal Reserve to start cutting interest rates. The Dow Jones Industrial Average (^DJI) rose around 0.1%. Meanwhile, the S&P 500 (^GSPC) rose around 0.3%, keeping potential new record high in sight. The Nasdaq Composite (^IXIC) moved up about 0.7%, with Apple (AAPL) stock rising after an upgrade from Jefferies (JEF) analysts and Tesla (TSLA) shares climbing after the EV maker produced more vehicles globally than expected in the second quarter even as sales plummeted. The benchmark S&P 500 and Nasdaq moved to session highs after President Trump announced a trade deal with Vietnam, lifting investor hopes that more agreements will come before the July 9 tariff pause deadline. Meanwhile, the labor market showed more signs of a cooldown in June. ADP data showed US private employers unexpectedly cut 33,000 jobs in the month, badly missing expectations of around 98,000 jobs added. It was the first month of job losses in the private sector in over two years. The data lays the ground for the release of the June US jobs report on Thursday, seen as a key factor for the Fed as investors bet an interest-rate cut could land sooner rather than later. According to CME data, the majority of Fed watchers still do not expect the central bank to cut rates in July. But almost all are betting on at least one rate cut by September, with over 20% now pricing in two cuts by that meeting. Read more: The latest on Trump's tariffs Trump's "One Big Beautiful Bill" is also in focus as it heads to the House after clearing the Senate thanks to Vice President JD Vance's tie-breaking vote. Insurance stocks fell across the board Wednesday, as the bill would slash federal health spending on Medicaid. But split Republican factions threaten to delay a potential final vote as Trump pushes to sign it by July 4. Footwear stocks led by Nike rose in morning trade on Wednesday after President Trump took to his social media platform Truth Social to share that he "made a Trade Deal with Vietnam." Nike (NKE), On Holding (ONON), Deckers (DECK), and Lululemon (LULU) spiked in immediate response to the news. Retail and footwear stocks tempered initial gains as Trump outlined details of the deal in a subsequent post, which said Vietnam will pay a 20% tariff on all good sent into the US and a 40% tariff on goods that are subject to transshipping, meaning routed through Vietnam with a different country of origin, like China. After an initial pop to rise as much as 4%, Nike stock was up about 1.7% in mid-morning trade on Wednesday. Shares of ON were up more than 3.5% to lead the rally among footwear names, while Deckers and Lululemon shares were fractionally higher. Read more here. Intel stock fell 3.7% after Reuters reported that the struggling chipmaker's new CEO is considering scrapping the company's long-awaited 18A technology for external customers — a chip manufacturing process that analysts have said is Intel's greatest hope for succeeding in a turnaround and becoming competitive with TSMC (TSM). According to Reuters, CEO Lip-Bu Tan has said that 18A was losing its appeal with customers. So far, Amazon (AMZN) and Microsoft (MSFT) have signed on to build their own chips using Intel's 18A process. Intel opened up its manufacturing business to outside clients in 2021 under former CEO Pat Gelsinger. But Wall Street analysts, investors, and executives grew exasperated with his strategy and what they saw as unrealistic goals for the business, which lost $13.4 billion in 2024 despite recording a revenue of $17.5 billion. Tan joined the company in March, and analysts and former executives told Yahoo Finance the new CEO needed to release 18A for outside customers to show that the company can execute after a history of delays and cancellations of its products and manufacturing processes. But Tan would instead like to focus on 14A, the manufacturing technology that is the successor to 18A. President Trump announced a trade deal with Vietnam, lifting investor sentiment that more agreements could come before the July 9 tariff-pause deadline. "The Terms are that Vietnam will pay the United States a 20% Tariff on any and all goods sent into our Territory, and a 40% Tariff on any Transshipping," Trump wrote on social media on Wednesday morning. "In return, Vietnam will do something that they have never done before, give the United States of America TOTAL ACCESS to their Markets for Trade," he added. "It is my opinion that the SUV or, as it is sometimes referred to, Large Engine Vehicle, which does so well in the United States, will be a wonderful addition to the various product lines within Vietnam," wrote Trump. Investors have been closely watching developments on the trade front as July 9 approaches — the deadline following a 90-day pause of reciprocal tariffs announced in April. The US recently announced a framework agreement with China, a major trading partner. Insurance stocks dropped across the board Wednesday following the passage during the prior trading session of Trump's "big, beautiful" tax and spending bill, which would gut federal healthcare spending over the next decade. UnitedHealth (UNH) fell nearly 3%, while Aetna parent company CVS Health (CVS) dropped over 2%. Cigna (CI) declined 3%, while Elevance Health (ELV) fell almost 9%. The megabill's provision to slash federal spending on Medicaid and Affordable Care Act marketplaces by about $1 trillion would leave almost 12 million people without insurance by 2034, NPR reported. Tesla stock climbed nearly 3% early Wednesday after the EV maker reported global electric vehicle deliveries that came in below Wall Street's low projections but produced more cars than expected. Tesla said Wednesday it delivered 384,122 EVs in the second quarter, less than the 389,407 projected by Wall Street analysts tracked by Bloomberg consensus estimates. The company's deliveries for the period marked a 13% drop from the prior year, but an increase from the 336,681 vehicles delivered in the first quarter. Read the full story here. Apple (AAPL) stock climbed about 1% Wednesday before the market open following an upgrade from analysts at Jefferies, who raised their rating to Hold from Underperform previously. Citing Counterpoint Research, Jefferies analyst Edison Lee said global iPhone sales rose 15% in April and May from the prior year, the strongest growth since the third quarter of 2021. Lee estimated that iPhone sales in China grew 19% in that period, partly due to targeted discounts and government subsidies as well as "pulled-in demand," or Chinese consumers buying phones ahead of anticipated tariffs. "This is a strong sign that AAPL is determined to defend market share in China, and Chinese consumers are still willing to buy iPhone at lower prices," Lee wrote. But he also said the release of the iPhone 17 in the second half of 2025 may not provide the boost Apple needs. Lee wrote that "sales could be at risk since there remains a lack of new features, and AI is not yet a game changer." Apple shares jumped 1.3% Tuesday following a report from Bloomberg that the iPhone maker is considering using AI technology from startups Anthropic ( or OpenAI ( to power a new version of Siri. Still, the stock was down 17% for the 12 months through Tuesday. Nvidia (NVDA) stock continued to retreat from its record high of $157.99 on Monday. Shares were down 1.2% in premarket trading. The AI chipmaker had reclaimed the top spot among the most valued companies worldwide in June, with a market cap of around $3.73 trillion, as of July 1. Microsoft (MSFT), the second most valued company, has a market cap of roughly $3.65 trillion. From Reuters: Read more here. Private employers unexpectedly cut 33,000 jobs in June, the latest signal of an intensifying slowdown in the US labor market. On Wednesday, data from ADP showed private payrolls fell by 33,000 last month in June, below the 29,000 job gains seen in May and the 98,000 additions expected by economists. This marked the first month of job losses in the private sector since March 2023. May's initial reading of 37,000 private payroll additions had been the lowest monthly total since March '23. "Though layoffs continue to be rare, a hesitancy to hire and a reluctance to replace departing workers led to job losses last month," ADP chief economist Nela Richardson said in the release. "Still, the slowdown in hiring has yet to disrupt pay growth." Read more here. Some of the world's most influential stocks are dragging the S&P 500 Index (^GSPC) down. The names Apple (AAPL), Tesla (TSLA) and Alphabet (GOOG, GOOGL) — part of the Mag 7 and synonymous with growth and value seem to be preventing the S&P 500 from reaching further highs. Bloomberg News reports: Read more here. Apple's (AAPL) is reportedly considering using AI tech from outside firms to power new version of Siri. Meta CEO Mark Zuckerberg is on an aggressive recruitment drive to poach top AI researchers and engineers. They're both signs of a key shift, Yahoo Finance's Hamza Shaban reports in today's Morning Brief: Read more here. Tesla (TSLA) is expected to report yet another quarter of declining global deliveries on Wednesday, though disappointing sales are nothing new for investors and analysts following the company. Data for June has brought a mixed message. Sales dropped for a sixth straight month in France, Sweden, Denmark and Italy, but rose in Norway and Spain — an early sign that the revamped Model Y is getting some buyers. Shares of Tesla were edging into the green in premarket before the quarterly data, following a 5% loss on Tuesday as CEO Elon Musk's feud with President Trump flared up again. Yahoo Finance's Pras Subramanian reports: Read more here. Earnings: No notable earnings releases.. Economic data: MBA Mortgage Applications (week ending June 27); ADP employment change (June); S&P Global US services PMI (May final); Challenger job cuts (May) Here are some of the biggest stories you may have missed overnight and early this morning: Apple and Meta are proving it: AI is going corporate Bets on 'Goldilocks' stocks bump up against reality Trump's 35% threat feeds Japan's worst-case tariff fears 'Irrational exuberance' stock gauge sparks fresh bubble worries Opinion: Musk is right about the Trump tax bill's failures Tesla's quarterly deliveries to fall short again Paramount settles Trump's '60 Minutes' suit for $16 million Bessent: Fed could lower interest rates by September Social Security checks slashed for millions this month Shares of Centene (CNC) tumbled over 25% in premarket trading after the healthcare insurer withdrew its financial guidance for 2025, warning that its earnings will fall far short of expectations. The company said late Tuesday that recent data showed that fewer people were enrolling in the Medicaid and Affordable Care Act marketplaces, and those who did enrol were sicker than expected. Those trends went against Centene's assumptions are likely to lead to a shortfall of $1.8 billion in federal payouts, the company said. Centene expects the issue to pull its full-year earnings per shares down by $2.75 a share. Wall Street had previously estimated adjusted EPS of $7.28. Shares of industry peers Elevance Health (ELV) and Oscar Health (OSCR) also struggled, down 4% and 7%, respectively. Here are some top stocks trending on Yahoo Finance in premarket trading: Centene Corporation (CNC) slumped 26% in premarket trading on Wednesday after withdrawing its financial guidance for 2025, warning that earnings will fall short of expectations. Centene is following in the footsteps of fellow insurance group, UnitedHealth (UNH), which pulled its guidance for the year and also replaced its chief executive. This latest news from Centene may add to investor nervousness when it comes to the insurance sector. Wolfspeed (WOLF) stock fell 8% before the bell today after the semiconductor company filed for a Chapter 11 bankruptcy. Intel (INTC) stock fell 1% in premarket trading following the new chief executive's plan to exploring a big change to its contract manufacturing business. If implemented, the new strategy for what Intel calls its "foundry" business would entail no longer marketing certain chipmaking technology, which the company had long developed, to external customers, the people said. If investors are expecting a seasonal lift for Asian equities this summer, they may have to think again. Tariff pressures and macroeconomic concerns have started to dampen sentiment. Bloomberg News reports: Read more here. Markets across the Asia-Pacific region saw mixed trading early morning on Wednesday, with investors eyeing the potential of US interest rate cuts and the fast-approaching July 9 tariff deadline for deals to be struck between the US and major trading partners worldwide. Singapore's benchmark, the Straits Times Index (^STI), gained 0.5% to hit a record high of 4009.15 points as of 00:20 (UTC-4). The move saw the index crossing past the 4000 threshold for the second time on record. Australia and Hong Kong led gains as Australia's S&P/ASX 200 (^AXJO) rose 0.4% and the Hang Seng Index (^HSI) popped 0.7%. Japan saw loss in the country's major gauge as the benchmark Nikkei 225 (^N225) slipped 0.7%. Korea's Kospi (^KS11) cratered 1.2% as Trump ratcheted up pressure on the country to finalize a trade deal. Mainland China's CSI 300 ( hovered near the baseline. Reuters reports: Footwear stocks led by Nike rose in morning trade on Wednesday after President Trump took to his social media platform Truth Social to share that he "made a Trade Deal with Vietnam." Nike (NKE), On Holding (ONON), Deckers (DECK), and Lululemon (LULU) spiked in immediate response to the news. Retail and footwear stocks tempered initial gains as Trump outlined details of the deal in a subsequent post, which said Vietnam will pay a 20% tariff on all good sent into the US and a 40% tariff on goods that are subject to transshipping, meaning routed through Vietnam with a different country of origin, like China. After an initial pop to rise as much as 4%, Nike stock was up about 1.7% in mid-morning trade on Wednesday. Shares of ON were up more than 3.5% to lead the rally among footwear names, while Deckers and Lululemon shares were fractionally higher. Read more here. Intel stock fell 3.7% after Reuters reported that the struggling chipmaker's new CEO is considering scrapping the company's long-awaited 18A technology for external customers — a chip manufacturing process that analysts have said is Intel's greatest hope for succeeding in a turnaround and becoming competitive with TSMC (TSM). According to Reuters, CEO Lip-Bu Tan has said that 18A was losing its appeal with customers. So far, Amazon (AMZN) and Microsoft (MSFT) have signed on to build their own chips using Intel's 18A process. Intel opened up its manufacturing business to outside clients in 2021 under former CEO Pat Gelsinger. But Wall Street analysts, investors, and executives grew exasperated with his strategy and what they saw as unrealistic goals for the business, which lost $13.4 billion in 2024 despite recording a revenue of $17.5 billion. Tan joined the company in March, and analysts and former executives told Yahoo Finance the new CEO needed to release 18A for outside customers to show that the company can execute after a history of delays and cancellations of its products and manufacturing processes. But Tan would instead like to focus on 14A, the manufacturing technology that is the successor to 18A. President Trump announced a trade deal with Vietnam, lifting investor sentiment that more agreements could come before the July 9 tariff-pause deadline. "The Terms are that Vietnam will pay the United States a 20% Tariff on any and all goods sent into our Territory, and a 40% Tariff on any Transshipping," Trump wrote on social media on Wednesday morning. "In return, Vietnam will do something that they have never done before, give the United States of America TOTAL ACCESS to their Markets for Trade," he added. "It is my opinion that the SUV or, as it is sometimes referred to, Large Engine Vehicle, which does so well in the United States, will be a wonderful addition to the various product lines within Vietnam," wrote Trump. Investors have been closely watching developments on the trade front as July 9 approaches — the deadline following a 90-day pause of reciprocal tariffs announced in April. The US recently announced a framework agreement with China, a major trading partner. Insurance stocks dropped across the board Wednesday following the passage during the prior trading session of Trump's "big, beautiful" tax and spending bill, which would gut federal healthcare spending over the next decade. UnitedHealth (UNH) fell nearly 3%, while Aetna parent company CVS Health (CVS) dropped over 2%. Cigna (CI) declined 3%, while Elevance Health (ELV) fell almost 9%. The megabill's provision to slash federal spending on Medicaid and Affordable Care Act marketplaces by about $1 trillion would leave almost 12 million people without insurance by 2034, NPR reported. Tesla stock climbed nearly 3% early Wednesday after the EV maker reported global electric vehicle deliveries that came in below Wall Street's low projections but produced more cars than expected. Tesla said Wednesday it delivered 384,122 EVs in the second quarter, less than the 389,407 projected by Wall Street analysts tracked by Bloomberg consensus estimates. The company's deliveries for the period marked a 13% drop from the prior year, but an increase from the 336,681 vehicles delivered in the first quarter. Read the full story here. Apple (AAPL) stock climbed about 1% Wednesday before the market open following an upgrade from analysts at Jefferies, who raised their rating to Hold from Underperform previously. Citing Counterpoint Research, Jefferies analyst Edison Lee said global iPhone sales rose 15% in April and May from the prior year, the strongest growth since the third quarter of 2021. Lee estimated that iPhone sales in China grew 19% in that period, partly due to targeted discounts and government subsidies as well as "pulled-in demand," or Chinese consumers buying phones ahead of anticipated tariffs. "This is a strong sign that AAPL is determined to defend market share in China, and Chinese consumers are still willing to buy iPhone at lower prices," Lee wrote. But he also said the release of the iPhone 17 in the second half of 2025 may not provide the boost Apple needs. Lee wrote that "sales could be at risk since there remains a lack of new features, and AI is not yet a game changer." Apple shares jumped 1.3% Tuesday following a report from Bloomberg that the iPhone maker is considering using AI technology from startups Anthropic ( or OpenAI ( to power a new version of Siri. Still, the stock was down 17% for the 12 months through Tuesday. Nvidia (NVDA) stock continued to retreat from its record high of $157.99 on Monday. Shares were down 1.2% in premarket trading. The AI chipmaker had reclaimed the top spot among the most valued companies worldwide in June, with a market cap of around $3.73 trillion, as of July 1. Microsoft (MSFT), the second most valued company, has a market cap of roughly $3.65 trillion. From Reuters: Read more here. Private employers unexpectedly cut 33,000 jobs in June, the latest signal of an intensifying slowdown in the US labor market. On Wednesday, data from ADP showed private payrolls fell by 33,000 last month in June, below the 29,000 job gains seen in May and the 98,000 additions expected by economists. This marked the first month of job losses in the private sector since March 2023. May's initial reading of 37,000 private payroll additions had been the lowest monthly total since March '23. "Though layoffs continue to be rare, a hesitancy to hire and a reluctance to replace departing workers led to job losses last month," ADP chief economist Nela Richardson said in the release. "Still, the slowdown in hiring has yet to disrupt pay growth." Read more here. Some of the world's most influential stocks are dragging the S&P 500 Index (^GSPC) down. The names Apple (AAPL), Tesla (TSLA) and Alphabet (GOOG, GOOGL) — part of the Mag 7 and synonymous with growth and value seem to be preventing the S&P 500 from reaching further highs. Bloomberg News reports: Read more here. Apple's (AAPL) is reportedly considering using AI tech from outside firms to power new version of Siri. Meta CEO Mark Zuckerberg is on an aggressive recruitment drive to poach top AI researchers and engineers. They're both signs of a key shift, Yahoo Finance's Hamza Shaban reports in today's Morning Brief: Read more here. Tesla (TSLA) is expected to report yet another quarter of declining global deliveries on Wednesday, though disappointing sales are nothing new for investors and analysts following the company. Data for June has brought a mixed message. Sales dropped for a sixth straight month in France, Sweden, Denmark and Italy, but rose in Norway and Spain — an early sign that the revamped Model Y is getting some buyers. Shares of Tesla were edging into the green in premarket before the quarterly data, following a 5% loss on Tuesday as CEO Elon Musk's feud with President Trump flared up again. Yahoo Finance's Pras Subramanian reports: Read more here. Earnings: No notable earnings releases.. Economic data: MBA Mortgage Applications (week ending June 27); ADP employment change (June); S&P Global US services PMI (May final); Challenger job cuts (May) Here are some of the biggest stories you may have missed overnight and early this morning: Apple and Meta are proving it: AI is going corporate Bets on 'Goldilocks' stocks bump up against reality Trump's 35% threat feeds Japan's worst-case tariff fears 'Irrational exuberance' stock gauge sparks fresh bubble worries Opinion: Musk is right about the Trump tax bill's failures Tesla's quarterly deliveries to fall short again Paramount settles Trump's '60 Minutes' suit for $16 million Bessent: Fed could lower interest rates by September Social Security checks slashed for millions this month Shares of Centene (CNC) tumbled over 25% in premarket trading after the healthcare insurer withdrew its financial guidance for 2025, warning that its earnings will fall far short of expectations. The company said late Tuesday that recent data showed that fewer people were enrolling in the Medicaid and Affordable Care Act marketplaces, and those who did enrol were sicker than expected. Those trends went against Centene's assumptions are likely to lead to a shortfall of $1.8 billion in federal payouts, the company said. Centene expects the issue to pull its full-year earnings per shares down by $2.75 a share. Wall Street had previously estimated adjusted EPS of $7.28. Shares of industry peers Elevance Health (ELV) and Oscar Health (OSCR) also struggled, down 4% and 7%, respectively. Here are some top stocks trending on Yahoo Finance in premarket trading: Centene Corporation (CNC) slumped 26% in premarket trading on Wednesday after withdrawing its financial guidance for 2025, warning that earnings will fall short of expectations. Centene is following in the footsteps of fellow insurance group, UnitedHealth (UNH), which pulled its guidance for the year and also replaced its chief executive. This latest news from Centene may add to investor nervousness when it comes to the insurance sector. Wolfspeed (WOLF) stock fell 8% before the bell today after the semiconductor company filed for a Chapter 11 bankruptcy. Intel (INTC) stock fell 1% in premarket trading following the new chief executive's plan to exploring a big change to its contract manufacturing business. If implemented, the new strategy for what Intel calls its "foundry" business would entail no longer marketing certain chipmaking technology, which the company had long developed, to external customers, the people said. If investors are expecting a seasonal lift for Asian equities this summer, they may have to think again. Tariff pressures and macroeconomic concerns have started to dampen sentiment. Bloomberg News reports: Read more here. Markets across the Asia-Pacific region saw mixed trading early morning on Wednesday, with investors eyeing the potential of US interest rate cuts and the fast-approaching July 9 tariff deadline for deals to be struck between the US and major trading partners worldwide. Singapore's benchmark, the Straits Times Index (^STI), gained 0.5% to hit a record high of 4009.15 points as of 00:20 (UTC-4). The move saw the index crossing past the 4000 threshold for the second time on record. Australia and Hong Kong led gains as Australia's S&P/ASX 200 (^AXJO) rose 0.4% and the Hang Seng Index (^HSI) popped 0.7%. Japan saw loss in the country's major gauge as the benchmark Nikkei 225 (^N225) slipped 0.7%. Korea's Kospi (^KS11) cratered 1.2% as Trump ratcheted up pressure on the country to finalize a trade deal. Mainland China's CSI 300 ( hovered near the baseline. Reuters reports: Sign in to access your portfolio
Yahoo
27 minutes ago
- Yahoo
S&P/TSX composite down in late-morning trading, U.S. stock markets higher
TORONTO — Canada's main stock index was down in late-morning trading, weighed down by losses in the utility and technology sectors, while U.S. stock markets climbed higher. The S&P/TSX composite index was down 11.94 points at 26,845.17. In New York, the Dow Jones industrial average was up 1.37 points at 44,496.31. The S&P 500 index was up 12.95 points at 6,210.96, while the Nasdaq composite was up 158.18 points at 20,361.07. The Canadian dollar traded for 73.34 cents US compared with 73.30 cents US on Monday. The August crude oil contract was up 50 cents US at US$65.95 per barrel. The August gold contract was up US$3.50 at US$3,353.30 an ounce. This report by The Canadian Press was first published July 2, 2025. Companies in this story: (TSX:GSPTSE, TSX:CADUSD) The Canadian Press Sign in to access your portfolio
Associated Press
39 minutes ago
- Associated Press
I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Company to host investor event on Tuesday, July 8th ROCKVILLE, Md., July 02, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the presentation of positive Phase 1b combination data for givastomig, in combination with nivolumab and mFOLFOX6, at the European Society for Medical Oncology Gastrointestinal Cancers Congress 2025 (ESMO GI 2025) in Barcelona (abstract #388MO) . Givastomig is a bispecific antibody targeting Claudin 18.2 and 4-1BB. I-Mab plans to host a virtual investor event on Tuesday, July 8th (register here ) to review these data. The Phase 1b data (NCT04900818) show a confirmed objective response rate (ORR) of 71% across all doses (12/17), and 83% (10/12) at doses selected for the ongoing dose expansion study (8 mg/kg and 12 mg/kg). Responses occurred in tumors with low levels of PD-L1 expression and/or Claudin 18.2 (CLDN18.2) expression, with favorable overall tolerability. There were no Grade 3 or greater events for nausea and vomiting, and only one Grade 3 TRAE for increased liver enzymes. The data are based on the results of the dose escalation part of a Phase 1b study evaluating the givastomig combination as first line therapy (1L) in patients with Claudin 18.2-positive gastric cancers (≥1+ IHC staining intensity in ≥1% of tumor cells). The primary endpoint is safety. The study enrolled only patients in the U.S. 'The positive Phase 1b combination data presented at ESMO GI bolster our confidence in givastomig's potential to be a best-in-class Claudin 18.2 directed therapy. Givastomig has been well tolerated when combined with immuno-oncology and chemotherapy, has shown a high objective response rate, with rapid onset and durable responses that have deepened over time, supported by consistent pharmacokinetic data and soluble 4-1BB induction,' said Phillip Dennis, MD, PhD, Chief Medical Officer of I-Mab. 'In addition, we are optimistic about the results from the 8 mg/kg and 12 mg/kg doses. These doses showed an ORR of 83%, with consistent responses across PD-L1 and Claudin 18.2 expression levels, and a favorable overall safety profile. These data further our conviction in the ongoing Phase 1b dose expansion study. We believe givastomig has broad potential in a number of gastric cancer settings and look forward to continued advancement of the program.' 'I am encouraged by the response rates, as well as the deepening of responses over time, demonstrated by the givastomig combination regimen in the Phase 1b dose escalation study that we presented today at ESMO GI. Despite approved therapies, targeted treatment options for gastric cancers continue to be limited. While the data are early, givastomig combination therapy demonstrates a high response rate across Claudin 18.2 and PD-L1 expression levels,' said Samuel J Klempner, MD, Associate Professor of Medicine at Massachusetts General Hospital. 'In addition, I have been pleased to observe that givastomig has a favorable overall tolerability profile with a low level of gastrointestinal side effects -- especially important for patients with gastric cancer. I look forward to participating in the ongoing givastomig clinical development program, and hope we may be able to expand the population of patients who may benefit from Claudin 18.2 directed agents.' Virtual Investor Event: Register ( here ) for the Post-ESMO GI 2025 Investor Event to be held on Tuesday, July 8th at 2:00 PM EDT. A replay of the webinar will be accessible on the Events page of the I-Mab website for 90 days. Fireside Chat Event with Lucid Capital Markets to Recap the Presentation: Tune in ( here ) for a fireside chat sponsored by Christopher Liu, PharmD, Managing Director at Lucid Capital Markets that will be accessible today at 2:00pm EDT on the Events page of the I-Mab website. A replay of the fireside chat will be available for 90 days. ESMO GI Presentation Details: A full copy of the ESMO GI presentation is available on the Publications and Presentations page of the I-Mab website here. Givastomig Phase 1b Dose Escalation Data Summary in 1L Gastric Cancers Patient Characteristics: Efficacy Results: Durability: Safety: About Givastomig Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting Claudin 18.2 (CLDN18.2)-positive tumor cells. It conditionally activates T cells through the 4-1BB signaling pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig is being developed for first line (1L) metastatic gastric cancers, with further potential in other solid tumors. In Phase 1 trials, givastomig has shown promising anti-tumor activity attributable to a potential synergistic effect of proximal interaction between CLDN18.2 on tumor cells and 4-1BB on T cells in the tumor microenvironment, while minimizing toxicities commonly seen with other 4-1BB agents. An ongoing Phase 1b study is evaluating givastomig for the treatment of gastric cancer in the 1L setting in combination with standard of care, nivolumab (an anti-PD-1 checkpoint inhibitor) plus chemotherapy, in dose escalation and dose expansion cohorts. Dose escalation is complete, and enrollment in the first dose expansion cohort (n=20) finished ahead of schedule. Enrollment continues to progress ahead of schedule in the second dose expansion cohort (n=20). The study builds on positive Phase 1 monotherapy data. Givastomig is being jointly developed through a global partnership with ABL Bio, in which I-Mab is the lead party and shares worldwide rights, excluding Greater China and South Korea, equally with ABL Bio. About I-Mab I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. The Company's differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB) designed to treat Claudin 18.2-positive gastric cancers. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed for first-line metastatic gastric cancers, with additional potential in other solid tumors. In Phase 1 trials, givastomig was observed to maintain strong tumor-binding and anti-tumor activity, attributable to a potential synergistic effect of proximal interaction with Claudin 18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents. For more information, please visit and follow us on LinkedIn and X. I-Mab Forward Looking Statements This announcement contains forward-looking statements. These statements are made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'will', 'expects', 'believes', 'designed to', 'anticipates', 'future', 'intends', 'plans', 'potential', 'estimates', 'confident', and similar terms or the negative thereof. I-Mab may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the SEC), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about I-Mab's beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the Company's pipeline and clinical development of I-Mab's drug candidates, including givastomig; the projected advancement of the Company's portfolio and anticipated milestones and related timing; the Company's expectations regarding the impact of data from ongoing and future clinical trials; the timing and progress of studies and trials (including with respect to patient enrollment); the potential benefits of givastomig; and the availability of data and information from ongoing studies and trials. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: I-Mab's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of I-Mab's drug candidates; I-Mab's ability to achieve commercial success for its drug candidates, if approved; I-Mab's ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab's reliance on third parties to conduct drug development, manufacturing and other services; and I-Mab's limited operating history and I-Mab's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the 'Risk Factors' section in I-Mab's annual report on Form 20-F filed with the SEC on April 3, 2025, as well as the discussions of potential risks, uncertainties, and other important factors in I-Mab's subsequent filings with the SEC. All forward-looking statements are based on information currently available to I-Mab. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. I-Mab Investor & Media Contacts PJ Kelleher LifeSci Advisors +1-617-430-7579 [email protected] [email protected]
